» Drug, Devices, and Supplements

» Physician Accountability

» Consumer Product Safety

» Worker Safety

» Health Care Delivery

» Auto and Truck Safety

» Global Access to Medicines

» Infant Formula Marketing


More Information on liraglutide (Victoza)

Acute Pancreatitis with Liraglutide

An analysis of MedWatch adverse event reports submitted to the Food and Drug Administration in the first two years following approval

June 5, 2014


Background: There have been conflicting reports concerning the pancreatic adverse effects of the incretin mimetic drug class of diabetes medications, with some studies suggesting a link between the drugs and acute pancreatitis. The present study applies objective criteria to the clinical information contained in Food and Drug Administration (FDA) MedWatch adverse event reports to determine the likelihood that the incretin mimetic drug liraglutide causes acute pancreatitis.

Methods: We requested the individual MedWatch case report forms from the FDA for all cases of “pancreatitis acute” associated with liraglutide in the FDA’s Adverse Event Reporting System that were reported to the agency between February 1, 2010, and December 31, 2011, roughly the first two years after liraglutide’s approval. Two researchers independently graded the cases for a causal link using the Naranjo adverse drug reaction probability criteria.

Results: There were 278 unique case reports of acute pancreatitis during liraglutide therapy. Pancreatitis occurred relatively soon after initiating therapy: 30% within one month and 72% within four months. Most cases (60%) required hospitalization. There were three deaths, two from complications of acute pancreatitis. Using the Naranjo criteria, we classified liraglutide as the “probable” causative agent in 51 cases, including 12 for which we deemed a causal link to be highly probable. There was one positive rechallenge, which was classified as a “definite” case of liraglutide-induced acute pancreatitis according to the Naranjo criteria.

Conclusions: Applying the Naranjo causality criteria to FDA MedWatch adverse event reports showed that liraglutide was a “probable” cause of 51 cases of acute pancreatitis as well as a “definite” cause of one case, the latter being the first documented report of a positive rechallenge. These results suggest a causal link between liraglutide and the occurrence of acute pancreatitis.

Next Page » Part I: Background

Copyright © 2017 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.